USCOM LIMITED — Regulatory Filings 2012

Jun 4, 2012

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

German study highlights new critical care market and endorses USCOM

Tuesday 5th of June 2012: Uscom (ASX code: UCM)

Noninvasive cardiac monitoring company Uscom Ltd today announced the publication of new independent peer reviewed research demonstrating USCOM’s role as a standard of care for accurate and important cardiac monitoring of critical care patients on ventilators.

The USCOM device already has major applications in pediatrics, emergency and intensive care medicine and anesthesia, as well as for management of adult and pediatric sepsis, hypertension, heart failure and for the guidance of cardiovascular fluid and drug therapy. This study identifies the accurate calibration of ventilators as an important clinical application for the patent protected USCOM platform technology, and a new and substantial market.

This new publication is based on a study performed on patients with pneumonia and septic shock admitted to the Intensive Care Unit of Ludwig-Maximilians-University Munich, which found USCOM was, “an accurate, easy to use, non-invasive device that detected irregularities in heart function and helped guide medical treatment.” and concluded that “USCOM constitutes an important tool for easy, rapid and reliable diagnosis and haemodynamic monitoring of critically ill patients.”

Executive Chairman of Uscom, Rob Phillips said, “This study shows that ventilators should be calibrated with USCOM. This is more far reaching, practice changing research which at some time will shift the medical monitoring market. Our sector dominating evidence has great value, and our focus is now to develop partnerships with established marketing, distribution and sales organizations which can efficiently and with scale deliver the USCOM technology into multiple revenue opportunities rapidly as practice responds to our mounting evidence.

Mr Phillips said , “These partnerships will allow us to deliver modular versions of USCOM into portable ultrasound units, monitoring suites, and now into ventilators, as well as continue with stand alone sales into current and new markets. These licensing partnerships are envisaged to deliver strong profitability to shareholders and be the foundation of the Uscom of the future.”

Ventilation of patients with impaired lung function is an increasingly common treatment in critical care medicine and inappropriate ventilator settings can impair cardiac function, making the patient worse. So an accurate measurement of cardiac output is critical for determining the optimal ventilation settings. Currently cardiac monitoring during ventilation is infrequent because the monitoring methods are invasive and/or inaccurate.

USCOM is cleared for use by the US Food & Drug Administration (FDA) and is sold in North America, South America, Europe, the Middle East, Australia, New Zealand, China and South East Asia.

References: Horster S, Stemmler HJ, Sparrer J, Tischer T, Hausman A, Geiger S. Mechanical ventilation with positive end-expiratory pressure in critically ill patients: comparison of CW-Doppler ultrasound cardiac output monitoring (USCOM) and thermodilution (PiCCO). Acta Cardiol 2012; 67(2): 177-185, doi: 10.2143/AC.67.2.2154208

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Tom Rowe Company Secretary secretary@uscom.com.au